Unknown

Dataset Information

0

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.


ABSTRACT: Recent studies have identified that constitutively active phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is an important feature of osteosarcoma, where it promotes cell proliferation, survival, and chemo-resistance. Here, we studied the therapeutic potential of NVP-BEZ235, a novel dual PI3K/mTOR dual inhibitor, on osteosarcoma cells in vivo and in vitro. NVP-BEZ235 was cytotoxic and cytostatic to a panel of osteosarcoma lines (MG-63, U2OS and SaOs-2), where it induce apoptosis and cell-cycle arrest. At the molecular level, NVP-BEZ235 inhibited PI3K-AKT-mTORC1 activation and downregulated cyclin D1/cyclin B1 expressions, while increasing MEK/Erk phosphorylation in osteosarcoma cells. MEK/Erk inhibitors PD98059 and MEK-162 increased NVP-BEZ235 activity on osteosarcoma cells. In vivo, oral NVP-BEZ235 inhibited U2OS xenograft in SCID mice, and its anti-tumor efficiency was further enhanced by MEK-162 co-administration. Taken together, our findings indicate that dual inhibition of PI3K and mTOR with NVP-BEZ235, either alone or in combination with MEK/Erk inhibitors, may be an efficient treatment for osteosarcoma.

SUBMITTER: Zhu YR 

PROVIDER: S-EPMC4622008 | biostudies-other | 2015

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC3348043 | biostudies-literature
| S-EPMC5840529 | biostudies-literature
| S-EPMC3502620 | biostudies-literature
| S-EPMC5746119 | biostudies-literature
| S-EPMC3606339 | biostudies-literature
| S-EPMC4876928 | biostudies-literature
| S-EPMC3078990 | biostudies-literature
| S-EPMC4943396 | biostudies-literature
| S-EPMC3934425 | biostudies-literature